Free Trial

Relmada Therapeutics (RLMD) Competitors

Relmada Therapeutics logo
$0.60 -0.02 (-2.45%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

RLMD vs. ENTX, ADAG, IVVD, SKYE, VNRX, ORMP, CHRS, IOBT, SRZN, and MGNX

Should you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include Entera Bio (ENTX), Adagene (ADAG), Invivyd (IVVD), Skye Bioscience (SKYE), VolitionRx (VNRX), Oramed Pharmaceuticals (ORMP), Coherus Oncology (CHRS), IO Biotech (IOBT), Surrozen (SRZN), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry.

Relmada Therapeutics vs. Its Competitors

Relmada Therapeutics (NASDAQ:RLMD) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Relmada Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500.

In the previous week, Relmada Therapeutics had 4 more articles in the media than Entera Bio. MarketBeat recorded 5 mentions for Relmada Therapeutics and 1 mentions for Entera Bio. Entera Bio's average media sentiment score of 1.87 beat Relmada Therapeutics' score of 0.47 indicating that Entera Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Relmada Therapeutics Neutral
Entera Bio Very Positive

Entera Bio has higher revenue and earnings than Relmada Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/A-$79.98M-$2.51-0.24
Entera Bio$180K479.50-$9.54M-$0.26-7.30

Relmada Therapeutics has a net margin of 0.00% compared to Entera Bio's net margin of -4,525.11%. Entera Bio's return on equity of -95.10% beat Relmada Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Relmada TherapeuticsN/A -181.26% -151.23%
Entera Bio -4,525.11%-95.10%-82.77%

Relmada Therapeutics presently has a consensus target price of $5.00, indicating a potential upside of 730.56%. Entera Bio has a consensus target price of $10.00, indicating a potential upside of 426.59%. Given Relmada Therapeutics' higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than Entera Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relmada Therapeutics
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25
Entera Bio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 20.7% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 10.4% of Entera Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Entera Bio beats Relmada Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Relmada Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RLMD vs. The Competition

MetricRelmada TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$19.98M$2.42B$5.50B$8.93B
Dividend YieldN/A1.79%5.38%4.12%
P/E Ratio-0.248.9426.2519.86
Price / SalesN/A665.31415.14113.78
Price / CashN/A154.3736.4957.06
Price / Book0.514.548.055.38
Net Income-$79.98M$31.16M$3.16B$248.50M
7 Day Performance11.48%0.15%1.78%2.78%
1 Month Performance-15.03%8.74%4.74%5.84%
1 Year Performance-79.87%2.17%35.81%20.06%

Relmada Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RLMD
Relmada Therapeutics
4.784 of 5 stars
$0.60
-2.3%
$5.00
+730.6%
-79.9%$19.98MN/A-0.2410News Coverage
ENTX
Entera Bio
2.8049 of 5 stars
$1.97
-0.8%
$10.00
+408.9%
+5.7%$90M$180K-7.5620Positive News
ADAG
Adagene
1.985 of 5 stars
$1.91
+0.3%
$8.00
+319.9%
-39.1%$89.51M$100K0.00260News Coverage
IVVD
Invivyd
3.3673 of 5 stars
$0.70
-6.0%
$5.85
+734.3%
-39.9%$89.48M$25.38M-0.58100News Coverage
Gap Up
SKYE
Skye Bioscience
2.1715 of 5 stars
$2.87
+32.9%
$16.60
+478.4%
-53.6%$88.91MN/A-3.5011High Trading Volume
VNRX
VolitionRx
1.6391 of 5 stars
$0.86
-6.5%
$3.50
+306.9%
+23.9%$88.61M$1.31M-2.3980Gap Down
High Trading Volume
ORMP
Oramed Pharmaceuticals
0.5728 of 5 stars
$2.11
-0.9%
N/A-18.0%$87.01M$1.34M-4.8010Gap Up
CHRS
Coherus Oncology
4.1908 of 5 stars
$0.73
-2.7%
$4.68
+544.5%
-52.8%$86.62M$266.96M-0.64330Positive News
IOBT
IO Biotech
3.234 of 5 stars
$1.30
flat
$9.33
+617.9%
+23.2%$85.64MN/A-0.9530Gap Up
SRZN
Surrozen
2.9623 of 5 stars
$9.02
-9.7%
$38.50
+326.8%
-17.7%$85.54M$10.65M-0.3680News Coverage
MGNX
MacroGenics
4.1192 of 5 stars
$1.32
+0.8%
$5.71
+332.9%
-70.7%$82.65M$149.96M-1.48430

Related Companies and Tools


This page (NASDAQ:RLMD) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners